AKT2 and acute lymphoblastic leukemia: Our in vitro and in vivo experiments verified that circADD2 could competitively bind to miR-149-5p to adversely affected ALL cell lines in vitro and in vivo, reducing AKT2 expression, and thereby inhibit the progression of ALL.